By: Alexandra Rimbu
Following a recent concern raised around thrombotic events (the event in which a blood clot forms inside a blood vessel), AstraZeneca offered its reassurance on the safety of its vaccine by conducting trials across the UK and EU in order to evaluate the vaccine’s effectiveness based on scientific evidence. The AstraZeneca report showed the vaccine to be 76% effective in preventing COVID-19 symptoms. Not only this, but the vaccine showed 100% efficacy against severe or critical disease or the need for hospitalization.
Reports from the UK and EU show that there have only been 15 events of DVT (deep vein thrombosis – a blood clot in a deep vein, usually in the legs) and only 22 events of pulmonary embolism (a condition in which one or more arteries in the lungs become blocked by a blood clot) reported among those given the AstraZeneca vaccine. This number is actually quite impressive, and it turned out to be much lower than would be expected to occur in populations of that size.
Ann Taylor, Chief Medical Officer, said: “Around 17 million people in the EU and UK have now received our vaccine, and the number of cases of blood clots reported in this group is lower than the hundreds of cases that would be expected among the general population. The nature of the pandemic has led to increased attention in individual cases and we are going beyond the standard practices for safety monitoring of licensed medicines in reporting vaccine events, to ensure public safety.”
In terms of quality, there have been no confirmed issues regarding any batch of the AstraZeneca vaccine used across Europe, or the rest of the world. However, additional testing has, and will continue to be conducted, although so far, testing has indicated no reason for concern, according to officials.
AstraZeneca has stated that they will always put the public’s safety first and that they encourage those invited to get the vaccine, and hopefully, we will soon overcome this pandemic.
For more information, please visit: